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Abstract 
Collagen glycosaminoglycan (CG) scaffolds have been clinically approved as an application 
for skin regeneration. The goal of this study was to examine if a CG scaffold is a suitable 
biomaterial for generating human bone tissue. Specifically, can the scaffold support human 
osteoblast growth and differentiation and how recombinant human transforming growth factor-
beta (TGF-β1) may enhance long term in vitro bone formation. We show human osteoblast 
attachment, infiltration and uniform distribution throughout the construct, reaching the centre 
within 14 days of seeding. We identified the fully differentiated osteoblast phenotype categorised 
by the temporal expression of alkaline phosphatase, collagen type 1, osteonectin, bone sialo 
protein, biglycan and osteocalcin. Mineralised bone formation was identified from 35 days post-
seeding using von Kossa and Alizarin S Red staining. Both gene expression and mineral staining 
suggest the benefit of introducing an initial high treatment of TGF-β1 (10ng/ml) followed by a low 
continuous treatment (0.2ng/ml) to enhance human osteogenesis on the scaffold. Osteogenesis 
coincided with a reduction in scaffold size and shape (up to 70% that of original).  A notable 
finding was that after 49 days of culture, core degradation was identified at the centre of the 
tissue engineered construct. This was not observed at earlier time points therefore a maximum of 
35 days in culture to be an appropriate end point for in vitro studies of these scaffolds. We 
conclude that the CG scaffold shows excellent potential as a biomaterial for human bone tissue 
engineering.   
 
Key words 
Bone Tissue Engineering, Osteoblast, Collagen, Scaffold, Transforming Growth Factor-ß1  
 
Introduction 
Currently, there exists a need to develop new bone graft substitutes as an alternative to 
conventional autografting and allografting treatments due to disadvantages like cost, scarcity of 
tissue, multiple surgical procedures and the risk of infection (Heng et al., 2004). Within bone 
tissue engineering, many scaffolds have been used to promote extracellular matrix formation and 
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mineralisation including bioactive glass, ceramics, titanium and polymers in an effort to substitute 
autologous bone for bone tissue engineering (Jones et al., 2007; Sun et al., 2006; Bokhari et al., 
2005; Itthichaisri et al., 2007). None of which however, may be classified as a bone graft 
substitute gold standard. An ideal scaffold should provide a suitable environment for tissue 
development. It should be highly porous allowing for protein absorption to facilitate cell 
attachment, infiltration and differentiation, be biocompatible, biodegradable, sterilizable, easily 
formed, shaped and stored. The use of various scaffolds for bone tissue engineering is increasing 
in clinical appeal and success.  
One potential substitute is type 1 collagen glycosaminoglycan (CG) based scaffolds which 
have been successfully used in a clinical setting as viable treatments for conjunctiva and 
epithelial regeneration (Yannas, 2001; Hsu et al., 2000; Compton et al., 1998). Much of this 
success is due to a number of useful properties including low antigenicity, biodegradability, high 
porosity and a high ligand density (O’ Brien et al., 2005). CG scaffolds are typically composed of 
type 1 collagen, an abundant connective protein in bone, and the glycosaminoglycan, chondroitin-
6 sulfate: a proteoglycan commonly found in bone matrix. Both components have been shown to 
be important factors for cell attachment, proliferation and differentiation (Pieper et al., 1999). The 
combination of these biologics, provide a more physiological substrate than that of synthetic 
polymer, ceramic and metal based scaffolds. These scaffolds are typically fabricated by 
lyophilising collagen based slurries to form a highly porous steril  scaffold.  
Recently, the CG scaffold has been successfully shown to support attachment and 
proliferation of various animal cell types including fibroblasts, chondrocytes, and neurons 
(Freyman et al., 2001a; McMahon et al., 2008). Studies in this laboratory have also shown that 
CG scaffolds may support in vitro osteogenesis (differentiation process of a progenitor cell into a 
mature bone forming osteoblast) of rat mesenchymal stem cells and mouse osteogenic cell line 
MC3T3 (Jaasma et al., 2008; Byrne et al., 2008). To date however, no studies have examined the 
ability of this scaffold to support long term human osteogenesis.  
The process of osteogenesis may be characterised by identifying temporally regulated bone 
formation markers; alkaline phosphatase, collagen type 1, osteopontin, bone sialoprotein, 
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osteonectin, biglycan and osteocalcin. Alkaline phosphates and collagen type 1 may be described 
as early bone formation markers and can appear in vitro within approximately 2 weeks of 
culturing under osteogenic conditions (Donahue et al., 2000).  Mid stage markers include 
osteopontin, bone sialo protein and osteonectin, these are often involved with the onset of crystal 
nucleation.  Late stage markers include osteocalcin and the small leucine rich proteoglycan, 
biglycan, and are expressed in bones and teeth and are important in regulating mineralization 
(Setzer et al., 2009).  
In order to assess human osteogenesis, a homogenous cell phenotype with controlled growth 
rate is beneficial which is a limitation of using primary human bone cell cultures. Expanding a 
primary cell population in vitro can result in them losing their ability to differentiate (Ter Brugge 
and Jansen, 2002). An alternative is to use osteosarcoma cell lines due to their homogeneity; 
however, they may be limited phenotypically by responding differently to growth hormones and 
factors (Subramaniam et al., 2002). The clonal human osteoblast cell line hFOB offers another 
alternative to reflect human bone biology. hFOB is a conditionally  immortalised cell line 
developed and described by Harris et al. (1995). The immortalized cells were transfected with a 
temperature sensitive plasmid (tsA58) of the SV40 large T antigen. This allows hFOB to be 
controlled between states of cellular growth; at 34.5oC the SV40 TAg gene is optimally expressed 
providing a proliferative phenotype whereas at 39oC it is not expressed, preventing proliferation 
but initiating differentiation.  hFOB have been shown to express high levels of alkaline 
phosphatase, collagen type 1, osteopontin, osteonectin, bone-sialo protein and osteocalcin. In 2D 
cultures, once confluent, they can form mineralized nodules and because of this they are a model 
cell line for studying human osteogenesis on our support scaffold (Donahue et al., 2000; Harris et 
al., 1995).  
Our bone tissue engineering triad principle consists of a CG scaffold seeded with hFOB cells 
exposed to osteogenic growth factors. Osteogenic growth factors typically include ascorbic acid 
to aid collagen synthesis and some form of phosphate donor which has been shown to be 
beneficial for in vitro mineralisation (Laurencin et al., 1996).  To this, vitamins D3 and K3 and 
recombinant human TGF-β1, key regulators of bone formation, were added as this combination 
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gave optimal results in our 2D culture studies (data not shown). TGF-β1 is the most abundant 
growth factor found in human bone. It alters osteoblast growth and differentiation by encouraging 
bone formation during maturation phases. TGF-β1 is quite potent with studies using 
concentrations in the range of 0.1-20ng/ml in vitro (Lieb et al., 2004). However conflicting 
evidence exists within the literature regarding optimal dosage of TGF-β1 in vitro. Studies have 
shown that best results for human bone formation occur with either a low continuous dose e.g. 
0.2ng/ml or one containing a single high concentration to induce osteogenesis e.g. 10ng/ml (Lieb 
et al., 2004; Zang et al., 2003).  
As no studies have examined long term human osteogenesis on CG scaffolds; the aim of this 
study was to investigate the potential of the CG scaffold as a suitable biomaterial to support 
human osteogenesis with applications for bone tissue engineering.  We examine the dose 
dependent response of TGF-β1 within our tissue engineered constructs due to the aforementioned 
conflicting evidence. Furthermore, we identify any structural changes that occurred within our 
scaffold as a result of long term osteogenic cultures. 
Initially an attachment, infiltration and distribution study of hFOB cells on CG scaffold was 
assessed up to 35 days (Study A). Subsequently, in order to determine if the scaffold can support 
human osteogenesis with the intention of developing a bone graft substitute hFOB cells were 
seeded onto CG scaffolds and cultured in osteogenic conditions up to 49 days (Study B). In this 
study we compare the effects of TGF-β1 on osteogenesis using two treatment concentrations; 
either a continuous low dosage (0.2ng/ml) or one single high dose (10ng/ml) followed by low 
continuous on human osteogenesis. 
 
Materials and methods 
Scaffold fabrication 
CG scaffolds were fabricated using a lyophilisation technique as described previously 
(O’Brien et al., 2005). Briefly, CG slurry was prepared by blending 0.5 wt % bovine collagen type 
1 (Integra Life Sciences, Plainsboro, NJ) with 0.05M acetic acid pH 3.2 containing 0.05 wt % 
shark cartilage derived chondroitin-6 sulfate  (Sigma-Aldrich, Germany). The slurry was blended 
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(Ultra turrax) then degassed in a vacuum oven prior to lyophilisation at -40oC, 50 mTorr for 24 
hours. Scaffolds were then cross linked by de-hydro thermal crosslinking at 105oC for 24 hours 
(VacuCell 22). Sheets of the finished product (thickness = 3.5mm; mean pore diameter = 96µm; 
porosity =99.5%; open interconnecting pores (O'Brien, 2005) were aseptically cut to size 
(10x10mm). 
 
Cell culture  
hFOB (ATCC, MA) pre-osteoblastic cells were cultured under standard conditions (5% CO2, 
37oC). Cells were routinely grown to 80% confluency in T175 culture flasks (Sarstedt, Ireland) 
containing culture media; a 1:1 ratio of Hams F12 and Dulbecco’s modified Eagle’s medium 
(without phenol red) (Gibco, UK), 10% fetal bovine serum (Sigma-Aldrich), 1% 
penicillin/streptomycin 10mg/ml (Sigma-Aldrich).  
 
Study A: Attachment, infiltration and distribution up to 35 days  
A total of 4x106 cells were seeded onto each scaffold in a dropwise manner and cultured in 
5mls of media for 24hrs. Scaffolds were replaced into new 6-well plates and cultured at 34.5oC for 
35 days; replenishing 2/3 of the media every 3 days. Cellular viability and histological analysis 
was determined up to 35 days of culture. 
 
Study B: Human osteogenesis study on CG scaffold up to 49 days 
4x106 cells were seeded onto CG scaffolds as described above; however culturing took place 
at 34.5oC for 14 days to allow for proliferation to the centre of the scaffold and at 39oC thereafter 
to allow for optimal differentiation. After 14 days constructs were replenished with osteogenic 
media to induce cellular differentiation: standard media containing 100µg/ml ascorbic acid, 10mM 
β-glycerolphosphate, recombinant human TGF-β1 (R&D Systems), 50nM Vitamin D3 (Sigma-
Aldrich)  and 10nM Vitamin K3 (Sigma-Aldrich).  
Two treatment groups were analysed based on TGF-β1 concentration: low continuous 
contained 0.2ng/ml TGF-β1 throughout exposure period. High TGF-β1 contained 10ng/ml TGF-β1 
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for 7 days then 0.2ng/ml for the remainder of the experiment. Two time points were assessed: 35 
days and 49 days (21 days and 35 days post exposure respectively). Histological analysis, 
chemical staining for mineralisation, gene expression and cell mediated scaffold contraction and 
mechanical testing was carried out on these samples. 
 
Viability of hFOB cells on CG scaffold 
Metabolic viability on the scaffold was determined by replacing media surrounding the cell 
seeded constructs and replenished with that containing 10% alamar blue dye (Bioscience). 
Scaffolds up to 35 days of culture were incubated on an orbital shaker for 4 hours (n=6). 100µl of 
media was read using a spectrophotometer at 570nm and 610nm. The percentage of reduced 
dye was calculated in accordance with manufacturer’s recommendations.  
 
Histological and chemical staining 
Hematoxylin & Eosin staining (H&E): Tissue engineered constructs were fixed in 4% 
paraformaldhyde for 30 minutes.  Dehydration and paraffin embedding was carried out using an 
automated tissue processor (ASP300, Leica) and cut into 10µm sections (RM2255, Leica). All 
stained sections were taken in a horizontal plain between 25-50% from the surface of the 
scaffold.  Standard H&E staining was carried out on de paraffinised sections. Images were 
captured on a digital microscope (NIS Elements, Nikon).  
Alizarin S Red staining: In order to stain calcium deposits, 10µm sections of scaffold was 
deparaffinised and stained with 2% Alizarin red (Sigma-Aldrich) filtered solution for 2 minutes. 
Sections were rinsed several times with dH20, dehydrated in xylene and mounted with DPX. 
Von Kossa staining: To determine the presence of phosphate based mineral, 10µm sections 
of scaffold was deparaffinised and brought to water.  Sections were stained by applying 2% silver 
nitrate (Sigma-Aldrich) solution for 1 hour under bright light. The reaction was stopped by adding 
the developing solution 1% sodium thiosulphate (Sigma-Aldrich) for 1 minute. Sections were 
counterstained with 0.5% Nuclear fast red (Sigma-Aldrich), dehydrated in xylene and mounted 
with DPX. 
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Gene expression  
RNA isolation: Cell seeded constructs were flash frozen in liquid nitrogen at each time point 
and stored at -80oC (n=3). RNA isolation from the constructs by homogenisation in RLT lysis 
buffer (Qiagen) using a rotor-stator homogeniser (Omni International). Cell lysates were 
centrifuged using QI Shredder columns (Qiagen) and RNA extracted using the RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions. RNA was concentration quantified was 
determined using a spectrophotometer (abs 260nm). 
Gene expression: Following RNA extraction Real time reverse transcription PCR was carried 
out for gene expression analysis.  Trace DNA was removed and RNA reverse transcribed using 
400ng total RNA with an RT kit (QuantiTect RT Kit, Qiagen) according to the manufacturer’s 
instructions. Realtime PCR was then carried out using the 7500 Real-Time PCR System (Applied 
Biosystems). The QuantiTect SYBR Green PCR Kit (Qiagen) was used, according to the 
manufacturer’s instructions, with QuantiTect Primers (Qiagen). Results were quantified for 
collagen type I, alkaline phosphatase, osteopontin/bone-sialo protein precursor, osteonectin, 
biglycan, and osteocalcin. Expression levels were assessed using the relative quantification ∆∆Ct 
method. β-actin acted as a house keeping control.  
 
Cell mediated scaffold contraction mechanical testing   
Scaffold contraction was measured using a vernier callipers up to 49 days culture. Cell 
seeded constructs post 49 days culture were analysed for mechanical stiffness using a Z050 
mechanical testing machine (Z050, Zwick/Reoll) fitted with a 5-N Load cell (n=6). Constructs were 
immersed in PBS and tested to 10% strain/minute unconfined wet compression testing. The 
modulus was calculated as the slope of a linear fit to the stress-strain curve over 2%-5% strain.   
 
Statistical analysis 
Statistical analysis was determined using sigma statistical software package SigmaStat 3.0. 
The statistical differences between 2 groups were calculated using the Students t test and 
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multiple groups were calculated using Kruskal-Wallis One Way Analysis of Variance on Ranks 
(ANOVA). Statistical significance was declared at p<0.05. 
 
Results 
 
Study A: attachment, infiltration and distribution up to 35 days 
hFOB cells were found to attach and infiltrate the scaffold with time (Fig. 1 a-h). Between 4 
and 7 days cells resided on the scaffold edge increasing in number (Fig. 1 a-b). Cells were 
observed at the scaffold centre after 14 days (Fig. 1 d). Scaffold pores contained numerous cells 
and matrix deposition was evident at 21 days along the surface of the tissue engineered 
construct. Scaffold size and pore structure changed with time particularly between 28 and 35 
days; a reduction in size was observed (Fig. 1 f-h). Constructs appeared confluent with cells at 35 
days both at the periphery and centre of the construct (Fig. 1 g-h); extra cellular matrix (ECM) 
deposition increased with time which coincided with a reduction in porosity particularly at 35 days. 
Alamar blue results gave a consistent 15% reduction of dye at all time points up to 35 days 
indicating a consistent cellular metabolic viability within the tissue engineered constructs.  
Study B: Human osteogenesis study on CG scaffold up to 49 days  
Histological results showed clear cell attachment, infiltration and uniform distribution 
throughout the constructs at 35 and 49 days (Fig. 2 a-d). An ext rnal layer or capsule of cells 
developed on the surface of the cell seeded construct becoming more prominent with time. There 
was no histological difference between low continuous or high TGF-β1 exposure between time 
points. ECM deposition and reduction in the original shape and porosity of the scaffold was 
observed at 35 and 49 days. After 35 and 49 days incubation positive mineralisation staining was 
observed in both TGF-β1 treatment groups however, high TGF-β1 treatment resulted in greater 
mineral staining than low continuous (Fig. 2 e, f, k, l).  
A notable finding of the study was the level of degradation and contraction within the 
construct over time. The homogenous pore structure was obsolete after 35 days of culture, 
replaced with cell matrix and contracted scaffold struts. By 49 days constructs became hollow at 
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the centre irrespective of treatment groups (Fig. 3 a-c). Cell viable regions (Fig. 3 a) of the 
construct surrounded the degraded core, however, mineralization remained evident on the 
construct (Fig. 3 b-c). 
Another interesting finding was the change in the amount of scaffold contraction with time 
(Fig. 4). Unseeded control scaffolds contracted in overall size by 50% of the original size 
however, this was more pronounced in cell seeded constructs (by 70% of the original size) at 49 
days incubation. Similarly, the scaffolds shape changed over time with the construct becoming 
more oval at 49 days (~3.5x3mm) from their original rectangular shape (10x10x3mm). 
Comparable changes in scaffold size and shape were observed in both low and high TGF-β1 
treatment groups.  
Collagen type 1 a marker for early stage osteogenesis was expressed in all cultured 
constructs. Low continuous TGF-β1 groups at day 35 and day 49 gave greater expression levels 
than treatments with high TGF-β1; this difference was significant at 35 and 49 days reducing by 
54% and 60% (p= 0.023; p= 0.026) (Fig. 5 a). Another marker of early osteogenesis, alkaline 
phosphatase showed similar trends to that of collagen type 1. There was a statistically significant 
difference in alkaline phosphatase expression between treatment groups; at 35 days an initial 
high treatment of TGF-β1 reduced expression levels relative to low treatment of TGF-β1 by 60% 
(p<0.024). This trend followed at 49 days where both treatments were statistically significantly 
reduced by 80% (low TGF-β1) and 100% (high TGF-β1) when compared to day 35 low TGF-β1 
(p= 0.021, p= 0.005) (Fig. 5 b).  
Osteonectin an important matrix protein expressed during osteoblast maturation shows 
similar trends to that of the early stage markers alkaline phosphatase and collagen type 1. 
Expression levels of osteonectin decrease by 70% and 84% with high TGF-β1 over low TGF-β1 
treatment at 35 and 49 days respectively (p= 0.012; p= 0.025) (Fig. 5 c). Both bone-sialo protein 
and the TGF-β1 regulated matrix protein biglycan showed trends of increasing expression levels 
by 38% and 57% respectively, for high TGF-β1 treatment over low continuous treatment at 49 
days (Fig. 5 d-e). Osteocalcin, a marker of late stage osteogenesis and mineralisation, showed a 
statistically significant increase in expression with time (p< 0.05). The higher dose of TGF-β1 
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resulted in a 40% increase in the expression of osteocalcin over that of the low dose at 49 days 
and a 700% increase between day 35 and day 49 with high TGF-β1 treatment (Fig. 5 f).  
Mechanical testing after 49 days of culture found a 5 fold increase in the stiffness of the 
tissue engineered constructs for both low (p= 0.01) and high (p< 0.0291) treatments of TGF-β1 
when compared to unseeded control scaffold (Fig. 6).   
 
Discussion 
The aim of this study was to investigate the potential of the CG scaffold as suitable 
biomaterial to support human osteogenesis with applications for bone tissue engineering.  
Furthermore, we examined the effects of recombinant human TGF-β1 within our tissue 
engineered constructs. 
In study A we showed hFOB cell infiltration from the scaffold edge to the centre by 14 days 
post-seeding with uniform distribution throughout the construct. As a result of this we incorporated 
a 14 day preculture in our subsequent long term study to provide the construct with the best start 
prior to the induction of osteogenesis. A fully confluent construct was found at 35 days of culture 
with maintained cell viability. Previous studies examining animal osteoblasts on scaffold have not 
shown such levels of confluency throughout the scaffold (Farrell et al., 2006; Tierney et al., 2008). 
We noted structural changes within our scaffold, such as a reduced porosity and overall scaffold 
size. This appeared to increase with higher cellular density and matrix deposition but did not 
affect cellular viability. This study illustrated that our CG scaffold is a good support structure for 
3D osteoblast attachment and growth.   
In study B, we examined the potential of our scaffold to support human osteogenesis. As 
osteogenesis proceeds following the onset of confluency; it was therefore decided to examine 
hFOB cells under osteogenic conditions containing TGF-β1 within the scaffold up to 49 days.  
TGF-β1 is linked with embryogenesis, tissue repair and bone regulation. Studies have shown 
its importance in bone formation by increasing osteoblast populations and their maturation (Zang 
et al., 2003). Given the conflicting literature pertaining to concentrations of TGF-β1 for human 
cultures, we assessed human osteogenesis on the scaffold using a previously optimised 
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osteogenic based media containing either a low continuous treatment of TGF-β1 (0.2ng/ml) or 
high TGF-β1 treatment  which consisted of an initial stimulating treatment (10ng/ml) followed by 
low continuous treatment.  
 The hFOB cell line has been described as a model cell line for osteogenesis with an ability to 
form mineralised nodules (Harris et al., 1995). However, not all studies using the hFOB cell line 
have produced mineral staining (Dhurjati et al., 2006; Subramaniam et al., 2002).  Our 
histological and chemical staining identified cell distribution and mineralization in the CG 
construct up to 49 days. We found that osteogenesis on the scaffold proceeded under both TGF-
β1 treatments; however, high TGF-β1 yielded a more mature osteoblastic phenotype capable of 
mineralising our scaffold in vitro. 
An important finding of this study for people trying to engineer bone in vitro with any scaffold 
was identifying core degradation at 49 days culture. The issue of core degradation of in vitro 
engineered tissues has been observed in other studies (Shea et al., 2000). In this study it was 
possibly due to a lack of diffusion of sufficient nutrients from the surrounding media as a result of 
extensive matrix and mineral deposition that formed in vitro. As this effect was not observed at 
the earlier time points, it suggests that 35 days might serve as an end point for in vitro cultures of 
these scaffolds. In order to overcome capsule formation and the development of core 
degradation, custom designed bioreactors may be used to encourage cellular infiltration at early 
stages of culture so that scaffolds may become confluent with c lls earlier, thus shortening the 
duration for the onset of osteogenesis. Perfusion flow bioreactors can also be used to enhance 
nutrient diffusion throughout the scaffold (Jaasma et al., 2008). 
A significant reduction in scaffold size was observed during long term incubations. Scaffold 
contraction may result in loss of contact between the implanted graft and the surrounding host 
tissue making integration of the repair tissue difficult (Lee et al., 2001). Contraction therefore 
could be limited by increasing the initial stiffness of the scaffold using crosslinking methods which 
should reduce scaffold contraction during culture. It should be noted that some scaffold 
contraction may however, be beneficial to promote osteogenesis by providing mechanical stimuli 
to cells during contraction (Freyman et al., 2001b).  
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In accordance with our mineral staining, we further identified stages of osteogenesis using 
Real Time PCR. Osteogenic markers were expressed in a temporal manner, similar to that found 
in both in vitro and in vivo studies (Stein et al., 1993; Bilezikian et al., 2001). Early markers of 
bone formation like collagen type 1 and alkaline phosphatase reduced in expression with time. 
Similarly, the late stage marker osteocalcin increased in expression with time. These expression 
patterns are consistent with the accepted model of osteogenesis indicating the development of a 
fully differentiated osteoblast phenotype on the CG scaffold (Stein et al., 1993). The timing of the 
expression of these osteogenic markers mimicked that more of in vivo osteogenesis than in vitro 
studies (Donahue et al., 2000; Stein et al., 1993). We expect this to be associated with levels of 
confluency in 3D structures and hypothesise this should be more relevant for in vivo clinical 
studies.  
Importantly, cell seeded constructs increased in mechanical strength; this increase in 
stiffness during culturing may be attributed to a) matrix formation following the induction of 
osteogenesis on the scaffold and b) contraction of the scaffold assisted by the action of the 
osteoblasts.  
 
Conclusions 
The CG scaffold supports attachment, infiltration and viability of human osteoblast cells. We 
have successfully demonstrated the ability of a CG scaffold to support human osteogenesis and 
form mineralised tissue in vitro. We show the importance of cellular infiltration and confluency of 
the scaffold as an important factor to allow osteogenesis to proceed, we identify the benefit of 
introducing an initial high dose of TGF-β1 for one week over a continuous low dose to enhance 
human osteogenesis and we determine 35 days in vitro culture as an end point for these 
scaffolds where later timepoints result in construct core degradation. Given these findings we 
conclude that CG scaffolds show excellent potential as a biomaterial for human bone tissue 
engineering applications.  
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Fig. 1 H&E staining of the cell seeded CG scaffold shows a clear infiltration and augmentation of 
hFOB cells within the scaffold over time (a-h) (10x magnification). At 4 and 7 days (a, b) cells 
reside along the scaffold edge. By 14 days (c) cells increase in number along the edge infiltrating 
into the centre of the construct (d); further cell proliferation and distribution was observed at 21,28 
and 35 days (e-g) resulting in a  fully confluent construct from edge (g) to centre (h)  
64x32mm (600 x 600 DPI)  
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Fig 2. Histological and mineral staining of the cell seeded collagen GAG scaffold (magnification 4x). 
Sections illustrate (a-d) H&E staining (e-h) Alizarin red and (i-l) von Kossa staining for 
mineralisation. Low TGF-β1 (a, e, i) and high TGF-β1 (b, f, j) represent 35 day cultures with 49 days 
represented as low TGF-β1 (c, g, k) and (d, h, l) high TGF-β1.   
H&E staining (a-d) illustrate highly infiltrated cell seeded constructs at all time points. Alizarin red 
and von Kossa staining showed greater staining for groups containing high treatment of TGF-β1 (f, j 
at 35 days and h, l at 49 days respectively)  
128x156mm (600 x 600 DPI)  
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Fig. 3 Sections of the scaffold centre following a 49 day culture under high TGF-β1 conditions 
showing necrotic core region (illustrated by white arrows) surrounded by (a) H&E stained cellular 
capsule that stained positive for mineralised tissue formation (b) Alizarin red and (c) Von Kossa 
(magnification 4x).    
43x14mm (600 x 600 DPI)  
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Fig. 4 Cells seeded onto scaffolds and cultured under high TGF-β1 osteogenic conditions up to 49 
days reduced in size by ~70%. Low and high TGF-β1 treatments showed similar levels of 
contraction  
39x18mm (600 x 600 DPI)  
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Fig. 5 Gene expression levels of osteogenic markers for cells seeded on CG scaffold at 35 and 49 
days culture (a-f). Higher TGF-β1 treatment resulted in greater expression of late stage osteogenic 
markers than low TGF-β1 treatments. A reduction in expression was observed for early markers of 
bone formation collagen type 1 (P<0.026) and alkaline phosphatase (p<0.024) with dosage and 
duration. Whereas mid and late stage markers increased with high TGF-β1 dosage at 49 days 
indicating a more differentiated osteoblastic phenotype; osteocalcin shows a 7 fold increase in 
expression between 35 and  49 days high TGF-β1 treatment groups  
96x72mm (600 x 600 DPI)  
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Fig. 6 Mechanical stiffness of cells seeded on scaffolds for 49 days under high osteogenic TGF-β1 
conditions. A 5 fold increase in stiffness was observed in low and high TGF-β1 treatment groups 
when compared to unseeded scaffolds (*p=0.01, **p<0.0291). No difference was observed 
between treatment groups of TGF-β1  
54x34mm (600 x 600 DPI)  
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Figure captions 
Fig. 1 a-h H&E staining of the cell seeded CG scaffold shows a clear infiltration and 
augmentation of hFOB cells within the scaffold over time (10x magnification). a At 4 and b 7 days 
cells reside along the scaffold edge. c By 14 days cells increase in number along the edge 
infiltrating into d the centre of the construct; e-f further cell proliferation and distribution was 
observed at 21 and 28 days. g At 35 days a fully confluent construct  was observed from the 
edge to h the centre of the construct  
 
Fig. 2 a-l Histological and mineral staining of the cell seeded collagen GAG scaffold 
(magnification 4x). Sections illustrate a-d H&E staining e-h Alizarin red and i-l von Kossa staining 
for mineralisation. Low TGF-β1 a, e, i and high TGF-β1 b, f, j represent 35 day cultures with 49 
days represented as low TGF-β1 c, g, k and high TGF-β1 d, h, l. 
H&E staining a-d illustrate highly infiltrated cell seeded constructs at all time points. Alizarin red 
and von Kossa staining showed greater staining for groups containing high treatment of TGF-β1; 
f, j at 35 days and h, l at 49 days respectively 
 
Fig. 3 a-c Sections of the scaffold centre following a 49 day culture under high TGF-β1 conditions 
showing necrotic core region (illustrated by white arrows) surrounded by a H&E stained cellular 
capsule that stained positive for mineralised tissue formation, b Alizarin red and c Von Kossa 
(magnification 4x).    
 
Fig. 4 Cells seeded onto scaffolds and cultured under high TGF-β1 osteogenic conditions up to 49 
days reduced in size by ~70%. Low and high TGF-β1 treatments showed similar levels of 
contraction  
 
Fig. 5 a-f Gene expression levels of osteogenic markers for cells seeded on CG scaffold at 35 
and 49 days culture. Higher TGF-β1 treatment resulted in greater expression of late stage 
osteogenic markers than low TGF-β1 treatments. A reduction in expression was observed for 
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early markers of bone formation collagen type 1 (p<0.026) and alkaline phosphatase (p<0.024) 
with dosage and duration. Whereas mid and late stage markers increased with high TGF-β1 
dosage at 49 days indicating a more differentiated osteoblastic phenotype; osteocalcin shows a 7 
fold increase in expression between 35 and  49 days high TGF-β1 treatment groups 
 
Fig. 6 Mechanical stiffness of cells seeded on scaffolds for 49 days under high osteogenic TGF-
β1 conditions. A 5 fold increase in stiffness was observed in low and high TGF-β1 treatment 
groups when compared to unseeded scaffolds (*p=0.01, **p<0.0291). No difference was 
observed between treatment groups of TGF-β1  
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